We developed a new class of biomimetic nanoparticles inspired by the ability of leukocytes to target inflammation and infiltrate inflamed tissues. By using the cell membrane proteins of different immune cells as building blocks, we created injectable nanoparticles able to avoid reticuloendothelial clearance, specifically target inflamed endothelium, cross the endothelial barrier, and increase accumulation of therapeutic payloads in target tissue.
The strategy of targeting inflammation, allowed us to use our biomimetic nanoparticle for the treatment of different inflammatory-based pathologies that affect humans including cancer, trauma, and infection. We are committed to focus their application on open orthopedic applications such as osteoporosis, osteoarthritis, bone metastasis and osteosarcoma.
Moreover, our platform is very versatile on its capacity of loading different molecules, ranging from small drugs, protein, cytokines, and nucleic acid such as miRNA and siRNA.